Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 3
1960 1
1961 3
1962 3
1963 3
1964 15
1965 9
1966 11
1967 11
1968 11
1969 8
1970 13
1971 11
1972 20
1973 21
1974 12
1975 16
1976 28
1977 17
1978 10
1979 14
1980 16
1981 21
1982 30
1983 27
1984 42
1985 55
1986 49
1987 41
1988 52
1989 70
1990 47
1991 49
1992 39
1993 52
1994 71
1995 57
1996 59
1997 58
1998 71
1999 80
2000 81
2001 81
2002 96
2003 110
2004 96
2005 126
2006 123
2007 104
2008 120
2009 111
2010 109
2011 124
2012 119
2013 129
2014 158
2015 147
2016 141
2017 122
2018 133
2019 147
2020 180
2021 213
2022 229
2023 196
2024 97

Text availability

Article attribute

Article type

Publication date

Search Results

4,171 results

Results by year

Filters applied: . Clear all
Page 1
ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts.
Enzan N, Matsushima S, Ikeda S, Okabe K, Ishikita A, Yamamoto T, Sada M, Miyake R, Tsutsui Y, Nishimura R, Toyohara T, Ikeda Y, Shojima Y, Miyamoto HD, Tadokoro T, Ikeda M, Abe K, Ide T, Kinugawa S, Tsutsui H. Enzan N, et al. Among authors: ikeda s. Circ Res. 2023 Apr 28;132(9):1110-1126. doi: 10.1161/CIRCRESAHA.122.322227. Epub 2023 Mar 28. Circ Res. 2023. PMID: 36974722 Free PMC article.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: ikeda s. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y, Kimura T; ONCO DVT Study Investigators. Yamashita Y, et al. Among authors: ikeda s. Circulation. 2023 Nov 21;148(21):1665-1676. doi: 10.1161/CIRCULATIONAHA.123.066360. Epub 2023 Aug 28. Circulation. 2023. PMID: 37638968 Clinical Trial.
Human β-defensin-3 attenuates atopic dermatitis-like inflammation through autophagy activation and the aryl hydrocarbon receptor signaling pathway.
Peng G, Tsukamoto S, Ikutama R, Nguyen HLT, Umehara Y, Trujillo-Paez JV, Yue H, Takahashi M, Ogawa T, Kishi R, Tominaga M, Takamori K, Kitaura J, Kageyama S, Komatsu M, Okumura K, Ogawa H, Ikeda S, Niyonsaba F. Peng G, et al. Among authors: ikeda s. J Clin Invest. 2022 Sep 1;132(17):e156501. doi: 10.1172/JCI156501. J Clin Invest. 2022. PMID: 35834333 Free PMC article.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. Among authors: ikeda s. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S. John T, et al. Among authors: ikeda s. Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19. Int J Clin Oncol. 2022. PMID: 35182247 Free PMC article. Clinical Trial.
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. Among authors: ikeda s. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Nishio M, Ohe Y, Ikeda S, Yokoyama T, Hayashi H, Fukuhara T, Sato Y, Tanaka H, Hotta K, Sugawara S, Daga H, Okamoto I, Kasahara K, Naito T, Li L, Gupta RG, Bushong J, Mizutani H. Nishio M, et al. Among authors: ikeda s. Int J Clin Oncol. 2023 Oct;28(10):1354-1368. doi: 10.1007/s10147-023-02390-2. Epub 2023 Aug 7. Int J Clin Oncol. 2023. PMID: 37548831 Free PMC article. Clinical Trial.
4,171 results